TITLE

The Repurposing Drugs in Oncology (ReDO) Project

AUTHOR(S)
Pantziarka, Pan; Bouche, Gauthier; Meheus, Lydie; Sukhatme, Vidula; Sukhatme, Vikas P.
PUB. DATE
June 2014
SOURCE
Ecancermedicalscience;2014, Vol. 8 Issue 413-446, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The Repurposing Drugs in Oncology (ReDO) Project seeks to repurpose well-known and well-characterised non-cancer drugs for new uses in oncology. The rationale for this project is presented, examining current issues in oncological drug development, challenges for health systems, and existing and future patient needs. In addition to discussing the advantages of repurposing, the paper also outlines some of the characteristics used in the selection of drug candidates by this project. Challenges in moving candidate drugs into clinical trial and subsequent practice are also discussed.
ACCESSION #
97255418

 

Related Articles

  • Phase I trials of antitumour agents: fundamental concepts. de Araujo Toloi, Diego; Fontes Jardim, Denis Leonardo; Gehm Hoff, Paulo Marcelo; Pimenta Riechelmann, Rachel Simões // Ecancermedicalscience;2015, Vol. 9 Issue 496-518, p1 

    Phase I trials are an important step in the development of new drugs. Because of the advancing knowledge of cancer's molecular biology, these trials offer an important platform for the development of new agents and also for patient treatment. Therefore, comprehension of their peculiar...

  • International models of investigator-initiated trials: implications for Japan. Trimble, E. L.; Ledermann, J.; Law, K.; Miyata, T.; Imamura, C. K.; Nam, B.-H.; Kim, Y.H.; Bang, Y.-J.; Michaels, M.; Ardron, D.; Amano, S.; Ando, Y.; Tominaga, T.; Kurokawa, K.; Takebe, N. // Annals of Oncology;Dec2012, Vol. 23 Issue 12, p3151 

    Background Academic/institutional investigator-initiated clinical trials benefit individuals and society by supplementing gaps in industry-sponsored clinical trials. Materials In May 2010, experts from Japan, the Republic of Korea, the UK, and the United States, met at a symposium in Tokyo,...

  • Tissue Acquisition in Clinical Trials-Essential for Progress. Ivy, S. Percy; Abrams, Jeffrey S. // JNCI: Journal of the National Cancer Institute;Apr2017, Vol. 109 Issue 4, p1 

    An introduction to the journal is presented in which the editors discuss the importance of tissue acquisition in clinical trials for cancer drug development.

  • USC/Norris Cancer Researchers Show Potential of Fighting Angiogenesis; Phase I Trial Shows Experimental Drug Is Safe and Lowers Level of Key Blood Protein.  // Ascribe Newswire: Health;6/11/2004, p76 

    A recent study has reported that the antiangiogenesis drug developed, called Veglin, not only is safe for patients with a wide variety of cancers, but also lowers levels of a key protein that tumors need to grow and stabilizes or even reverses some cancers for a period. Researchers presented...

  • A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer. Takeda, Y.; Tsuduki, E.; Izumi, S.; Hojo, M.; Kamimura, M.; Naka, G.; Kobayashi, K.; Kudo, K. // British Journal of Cancer;12/12/2005, Vol. 93 Issue 12, p1341 

    We conducted a phase I/II study in patients with advanced non-small-cell lung cancer (NSCLC) to increase the therapeutic index of the cisplatin–irinotecan combination by institution of an anti-late-diarrhoeal program (ADP). A total of 77 chemotherapy-naive patients with advanced NSCLC...

  • ATAC TRIAL: REPORTS OF INTERIM RESULTS CAN BE MISLEADING. Goodare, Heather; Dimmer, Clare; Page, Kathy // BMJ: British Medical Journal (International Edition);6/14/2003, Vol. 326 Issue 7402, p1329 

    Presents a letter about the misleading results of the arimidex, tamoxifen alone or in combination trial (ATAC). Problems in patients with endometrial cancer; Unknown adverse reactions; Effects of early reporting rules.

  • Phase II study of nedaplatin and irinotecan for elderly patients with advanced non-small cell lung cancer. Oshita, Fumihiro; Yamada, Kouzo; Saito, Haruhiro; Noda, Kazumasa; Hamanaka, Nobuyuki; Ikehara, Mizuki // Journal of Experimental Therapeutics & Oncology;2004, Vol. 4 Issue 4, p343 

    We conducted a phase II study of combination chemotherapy with nedaplatin (NP) with irinotecan (CPT) to determine the effects against unresectable non-small cell lung cancer (NSCLC) and to determine the qualitative and quantitative toxicities of this combination chemotherapy in 70 years or older...

  • Despite Positive Studies, Popularity of Chemoprevention Drugs Increasing Slowly. Zielinski, Sarah L. // JNCI: Journal of the National Cancer Institute;10/6/2004, Vol. 96 Issue 19, p1410 

    Reports on the slow acceptance of chemoprevention drugs among physicians and patients in the U.S. Percentage of chemoprevention drugs that has completed phase III clinical trials; Approval of tamoxifen for breast cancer prevention by the U.S. Food and Drug Administration; Reasons why physicians...

  • Trastuzumab: is the new evidence revolutionary? Munshi, Anusheel; Singh, Pritanjali; Jalali, Rakesh // Journal of Cancer Research & Therapeutics;Jul-Sep2006, Vol. 2 Issue 3, p144 

    A few years back, the survival benefit of trastuzumab in HER 2 positive breast cancer patients presenting with metastatic disease was proven in a randomized setting. Recently a number of randomized trials have reported their results in the adjuvant setting in HER 2 positive patients. These...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics